Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
NCT ID: NCT01225172
Last Updated: 2020-08-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
77 participants
INTERVENTIONAL
2010-12-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
NCT00549822
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
NCT01082068
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
NCT00796107
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
NCT00573755
Letrozole in Preventing Breast Cancer in Postmenopausal Women
NCT00090857
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BMS-754807
BMS-754807
Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
BMS-754807 + letrozole
BMS-754807
Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
letrozole
Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-754807
Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
letrozole
Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease progression following non-steroidal aromatase inhibitor treatment
Exclusion Criteria
* Medical condition requiring chronic steroids
* History of Type 1 or 2 Diabetes
* Uncontrolled or significant cardiovascular (CV) disease
* Concomitant second malignancies
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ Of Al At Birmingham
Birmingham, Alabama, United States
Mayo Clinic Arizona
Scottsdale, Arizona, United States
Sharp Clinical Oncology Research
San Diego, California, United States
Mayo Clinic
Jacksonville, Florida, United States
University Of Chicago Medical Center
Chicago, Illinois, United States
Illinois Cancercare, Pc
Peoria, Illinois, United States
Indiana University Health Goshen Center For Cancer Care
Goshen, Indiana, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, United States
Oncology Care Associates, P.A.
Wheaton, Maryland, United States
Masonic Cancer Ctr, University Of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Unv. Of Nc At Chapel Hill
Chapel Hill, North Carolina, United States
Unv. Of Nc At Chapel Hill
Chapel Hill, North Carolina, United States
Presbyterian Hospital Cancer Research
Charlotte, North Carolina, United States
Duke University Medical Center-Dept Of Medicine
Durham, North Carolina, United States
Ut Md Anderson Can Ctr.
Houston, Texas, United States
Ut Md Anderson Can Ctr.
Houston, Texas, United States
University Of Virginia Health System
Charlottesville, Virginia, United States
University Of Wisconsin
Madison, Wisconsin, United States
University Of Wisconsin
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS clinical trial educational resource
Investigator Inquiry form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA191-011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.